Literature DB >> 32292547

Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer.

Xinglin Li1, Shanchao Wu2, Guoqiang Dong2, Shuqiang Chen2, Zonglin Ma1, Dan Liu1, Chunquan Sheng2.   

Abstract

In order to improve the antitumor potency of the natural product evodiamine, novel boron-containing evodiamine derivatives were designed by incorporating boronic acid and boronate as trigger units. Boronate derivative 13a could be triggered by reactive oxygen species (ROS) in the HCT116 colon cancer cell line and showed excellent antitumor activity in vitro and in vivo. It induced apoptosis in HCT116 cancer cells in a dose-dependent manner and cell growth arrest at the G2 phase.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32292547      PMCID: PMC7153022          DOI: 10.1021/acsmedchemlett.9b00513

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

1.  Photoactivatable Organic Semiconducting Pro-nanoenzymes.

Authors:  Jingchao Li; Jiaguo Huang; Yan Lyu; Jingsheng Huang; Yuyan Jiang; Chen Xie; Kanyi Pu
Journal:  J Am Chem Soc       Date:  2019-02-20       Impact factor: 15.419

2.  Recent developments in the chemistry and biological applications of benzoxaboroles.

Authors:  Agnieszka Adamczyk-Woźniak; Krzysztof M Borys; Andrzej Sporzyński
Journal:  Chem Rev       Date:  2015-05-27       Impact factor: 60.622

Review 3.  Boron in drug design: Recent advances in the development of new therapeutic agents.

Authors:  Guilherme Felipe Santos Fernandes; William Alexander Denny; Jean Leandro Dos Santos
Journal:  Eur J Med Chem       Date:  2019-07-03       Impact factor: 6.514

4.  An activatable prodrug for the treatment of metastatic tumors.

Authors:  Eun-Joong Kim; Sankarprasad Bhuniya; Hyunseung Lee; Hyun Min Kim; Chaejoon Cheong; Sukhendu Maiti; Kwan Soo Hong; Jong Seung Kim
Journal:  J Am Chem Soc       Date:  2014-09-19       Impact factor: 15.419

Review 5.  Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy.

Authors:  Miguel López-Lázaro
Journal:  Cancer Lett       Date:  2006-12-05       Impact factor: 8.679

6.  Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.

Authors:  Guoqiang Dong; Chunquan Sheng; Shengzheng Wang; Zhenyuan Miao; Jianzhong Yao; Wannian Zhang
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

Review 7.  Boronic acid compounds as potential pharmaceutical agents.

Authors:  Wenqian Yang; Xingming Gao; Binghe Wang
Journal:  Med Res Rev       Date:  2003-05       Impact factor: 12.944

Review 8.  Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018).

Authors:  Alessio Nocentini; Claudiu T Supuran; Jean-Yves Winum
Journal:  Expert Opin Ther Pat       Date:  2018-05-11       Impact factor: 6.674

9.  Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

Authors:  Tsutomu Akama; Stephen J Baker; Yong-Kang Zhang; Vincent Hernandez; Huchen Zhou; Virginia Sanders; Yvonne Freund; Richard Kimura; Kirk R Maples; Jacob J Plattner
Journal:  Bioorg Med Chem Lett       Date:  2009-03-09       Impact factor: 2.823

Review 10.  Pharmacological actions of multi-target-directed evodiamine.

Authors:  Hui Yu; Hongwei Jin; Wuzhuang Gong; Zhanli Wang; Huaping Liang
Journal:  Molecules       Date:  2013-01-31       Impact factor: 4.411

View more
  4 in total

Review 1.  Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets.

Authors:  Richard Kwamla Amewu; Patrick Opare Sakyi; Dorcas Osei-Safo; Ivan Addae-Mensah
Journal:  Molecules       Date:  2021-11-25       Impact factor: 4.411

2.  Antitumor Effects of Evodiamine in Mice Model Experiments: A Systematic Review and Meta-Analysis.

Authors:  Cong Yin; Jing Cheng; Hongbing Peng; Shijun Yuan; Keli Chen; Juan Li
Journal:  Front Oncol       Date:  2021-11-09       Impact factor: 6.244

3.  Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis.

Authors:  Ze-Bo Jiang; Ju-Min Huang; Ya-Jia Xie; Yi- Zhong Zhang; Chan Chang; Huan-Ling Lai; Wenjun Wang; Xiao-Jun Yao; Xing-Xing Fan; Qi-Biao Wu; Chun Xie; Mei-Fang Wang; Elaine Lai-Han Leung
Journal:  J Exp Clin Cancer Res       Date:  2020-11-19

4.  Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Farid Hashemi; Ebrahim Rahmani Moghadam; Mehdi Raei; Mahshad Kalantari; Shima Tavakol; Reza Mohammadinejad; Masoud Najafi; Franklin R Tay; Pooyan Makvandi
Journal:  ACS Comb Sci       Date:  2020-10-23       Impact factor: 3.784

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.